drugset / Trial / NCT00313612

Oxaliplatin and Topotecan in Advance Ovarian Cancer

NCT00313612 ↗

Phase 2 Terminated 39 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well giving oxaliplatin together with topotecan works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as oxaliplatin and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Timeline

Start
2006-01
Primary completion
2011-05
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous
Subject Topotecan Small molecule 0.4 mg/m2 Intravenous